Janiczek Wealth Management LLC Has $84,000 Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Janiczek Wealth Management LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQVFree Report) by 54.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 362 shares of the medical research company’s stock after selling 439 shares during the period. Janiczek Wealth Management LLC’s holdings in IQVIA were worth $84,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. AdvisorNet Financial Inc grew its stake in shares of IQVIA by 327.6% in the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares in the last quarter. BKM Wealth Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth $32,000. ST Germain D J Co. Inc. bought a new stake in shares of IQVIA in the 2nd quarter worth $33,000. Activest Wealth Management bought a new stake in shares of IQVIA in the 4th quarter worth $35,000. Finally, Live Oak Investment Partners bought a new stake in shares of IQVIA in the 4th quarter worth $41,000. Institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on IQV. BTIG Research began coverage on shares of IQVIA in a research note on Tuesday, February 13th. They issued a “buy” rating and a $285.00 target price for the company. Truist Financial increased their price target on shares of IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. Robert W. Baird increased their price target on shares of IQVIA from $226.00 to $251.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th. Finally, SVB Leerink began coverage on shares of IQVIA in a research report on Monday, February 26th. They set an “outperform” rating and a $290.00 price target for the company. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $256.80.

Check Out Our Latest Report on IQVIA

IQVIA Price Performance

Shares of NYSE:IQV opened at $234.23 on Friday. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $42.51 billion, a PE ratio of 32.13, a P/E/G ratio of 2.30 and a beta of 1.50. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a 50-day moving average price of $243.47 and a two-hundred day moving average price of $220.60.

IQVIA (NYSE:IQVGet Free Report) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The firm had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same period in the prior year, the firm posted $2.54 earnings per share. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. Equities analysts forecast that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

IQVIA Company Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVFree Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.